芬诺单抗联合贝伐单抗作为晚期肝细胞癌一线治疗的经济评价
Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma.
摘要(中文译文)
从中国医疗体系的角度，比较双药组（finotonlimab联合贝伐珠单抗生物类似药SCT510）与索拉非尼作为晚期肝细胞癌（HCC）一线治疗的成本效果。基于一项III期临床试验的结果，构建了三状态分区生存模型。模型的主要结局包括总成本、总质量调整生命年（QALYs）和增量成本效果比（ICER）。采用成本效果分析评估双药组相较于索拉非尼组作为晚期HCC一线治疗的经济性。模型周期长度设为3周，时间跨度为10年，贴现率为4.5%。意愿支付（WTP）阈值设为中国2025年人均国内生产总值（GDP）的三倍（299,400元人民币）。进行单因素敏感性分析和概率敏感性分析以评估结果的稳健性。双药组相较于索拉非尼组基于QALYs计算的ICER为859,053.76元/QALY，高于WTP阈值（299,400元）。单因素敏感性分析表明，PD状态的效用值、PFS状态的效用值、finotonlimab和贝伐珠单抗生物类似药的成本等参数对ICER有显著影响，而其他参数影响较小。基础案例分析结果稳健。概率敏感性分析显示，在WTP阈值为299,400元时，双药组具有成本效果的概率为0%。当WTP阈值约为842,000元时，两组具有成本效果的概率相等。概率敏感性分析结果与基础案例分析一致。从中国医疗体系的角度来看，finotonlimab联合贝伐珠单抗生物类似药作为晚期HCC一线治疗不具有成本效果。
Abstract
To compare the cost-effectiveness of dual-agent group (finotonlimab combined with a bevacizumab biosimilar) (SCT510) versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HCC) from the perspective of the Chinese healthcare system. Based on the results of a Phase III clinical trial, a three-state partitioned survival model was constructed. The primary outcomes of the model included total costs, total quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER). Cost-effectiveness analysis was employed to evaluate the economic efficiency of the dual-agent group compared to the sorafenib group as first-line treatment for advanced HCC. The model cycle length was set at 3 weeks, with a time horizon of 10 years and a discount rate of 4.5%. The willingness-to-pay (WTP) threshold was set at three times China's 2025 per capita gross domestic product (GDP) (299,400 CNY). One-way sensitivity analysis and probabilistic sensitivity analysis were conducted to assess the robustness of the results. The ICER for the dual-agent group compared to the sorafenib group, calculated based on QALYs, was 859,053.76 CNY/QALY, which is higher than the WTP threshold (299,400 CNY). One-way sensitivity analysis indicated that parameters such as utility value in the PD state, utility value in the PFS state, the cost of finotonlimab and bevacizumab biosimilar had a significant impact on the ICER, while other parameters had minimal influence. The base-case analysis results were robust. Probabilistic sensitivity analysis showed that at a WTP threshold of 299,400 CNY, the probability of the dual-agent group being cost-effective was 0%. When the WTP threshold was approximately 842,000 CNY, the two groups had equal probability of being cost-effective. The probabilistic sensitivity analysis results were consistent with the base-case analysis. From the perspective of the Chinese healthcare system, finotonlimab combined with a bevacizumab biosimilar is not cost-effective as first-line treatment for advanced HCC.
如何引用
AMA
XueYin Xu, Lian Tang, XiangHua Piao, ShaoQing Zhan, Yong Chen, PanFeng Feng. Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma.. PloS one. 2026; doi:10.1371/journal.pone.0349044.
APA
XueYin Xu, Lian Tang, XiangHua Piao, ShaoQing Zhan, Yong Chen, PanFeng Feng (2026). Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma.. PloS one. https://doi.org/10.1371/journal.pone.0349044
GB/T 7714
XueYin Xu, Lian Tang, XiangHua Piao, ShaoQing Zhan, Yong Chen, PanFeng Feng. Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma.[J]. PloS one, 2026 doi:10.1371/journal.pone.0349044.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出